ARTV Quote, Financials, Valuation and Earnings

Kezar Life Sciences, Inc. has a net margin of -5562.95% compared to Artiva Biotherapeutics, Inc.'s net margin of --. Artiva Biotherapeutics, Inc.'s return on equity of -47.44% beat Kezar Life Sciences, Inc.'s return on equity of -58.35%.

Artiva Biotherapeutics, Inc. has a consensus price target of $17.00, signalling upside risk potential of 298.13%. On the other hand Kezar Life Sciences, Inc. has an analysts' consensus of $6.00 which suggests that it could fall by -5.36%. Given that Artiva Biotherapeutics, Inc. has higher upside potential than Kezar Life Sciences, Inc., analysts believe Artiva Biotherapeutics, Inc. is more attractive than Kezar Life Sciences, Inc..

Artiva Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kezar Life Sciences, Inc. has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.462%.

Artiva Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kezar Life Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Artiva Biotherapeutics, Inc. pays -- of its earnings as a dividend. Kezar Life Sciences, Inc. pays out -- of its earnings as a dividend.

Artiva Biotherapeutics, Inc. quarterly revenues are --, which are smaller than Kezar Life Sciences, Inc. quarterly revenues of --. Artiva Biotherapeutics, Inc.'s net income of -$21.5M is lower than Kezar Life Sciences, Inc.'s net income of -$11.2M. Notably, Artiva Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Kezar Life Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artiva Biotherapeutics, Inc. is 46.79x versus -- for Kezar Life Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Olema Pharmaceuticals, Inc. has a net margin of -5562.95% compared to Artiva Biotherapeutics, Inc.'s net margin of --. Artiva Biotherapeutics, Inc.'s return on equity of -47.44% beat Olema Pharmaceuticals, Inc.'s return on equity of -45.61%.

Artiva Biotherapeutics, Inc. has a consensus price target of $17.00, signalling upside risk potential of 298.13%. On the other hand Olema Pharmaceuticals, Inc. has an analysts' consensus of $46.00 which suggests that it could grow by 67.58%. Given that Artiva Biotherapeutics, Inc. has higher upside potential than Olema Pharmaceuticals, Inc., analysts believe Artiva Biotherapeutics, Inc. is more attractive than Olema Pharmaceuticals, Inc..

Artiva Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Olema Pharmaceuticals, Inc. has a beta of 1.870, suggesting its more volatile than the S&P 500 by 86.967%.

Artiva Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Olema Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Artiva Biotherapeutics, Inc. pays -- of its earnings as a dividend. Olema Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Artiva Biotherapeutics, Inc. quarterly revenues are --, which are smaller than Olema Pharmaceuticals, Inc. quarterly revenues of --. Artiva Biotherapeutics, Inc.'s net income of -$21.5M is higher than Olema Pharmaceuticals, Inc.'s net income of -$42.2M. Notably, Artiva Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Olema Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artiva Biotherapeutics, Inc. is 46.79x versus -- for Olema Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ovid Therapeutics, Inc. has a net margin of -5562.95% compared to Artiva Biotherapeutics, Inc.'s net margin of -9210.61%. Artiva Biotherapeutics, Inc.'s return on equity of -47.44% beat Ovid Therapeutics, Inc.'s return on equity of -59.7%.

Artiva Biotherapeutics, Inc. has a consensus price target of $17.00, signalling upside risk potential of 298.13%. On the other hand Ovid Therapeutics, Inc. has an analysts' consensus of $4.05 which suggests that it could grow by 127.47%. Given that Artiva Biotherapeutics, Inc. has higher upside potential than Ovid Therapeutics, Inc., analysts believe Artiva Biotherapeutics, Inc. is more attractive than Ovid Therapeutics, Inc..

Artiva Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ovid Therapeutics, Inc. has a beta of 0.045, suggesting its less volatile than the S&P 500 by 95.453%.

Artiva Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ovid Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Artiva Biotherapeutics, Inc. pays -- of its earnings as a dividend. Ovid Therapeutics, Inc. pays out -- of its earnings as a dividend.

Artiva Biotherapeutics, Inc. quarterly revenues are --, which are smaller than Ovid Therapeutics, Inc. quarterly revenues of $132K. Artiva Biotherapeutics, Inc.'s net income of -$21.5M is lower than Ovid Therapeutics, Inc.'s net income of -$12.2M. Notably, Artiva Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Ovid Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artiva Biotherapeutics, Inc. is 46.79x versus 19.14x for Ovid Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rocket Pharmaceuticals, Inc. has a net margin of -5562.95% compared to Artiva Biotherapeutics, Inc.'s net margin of --. Artiva Biotherapeutics, Inc.'s return on equity of -47.44% beat Rocket Pharmaceuticals, Inc.'s return on equity of -64.31%.

Artiva Biotherapeutics, Inc. has a consensus price target of $17.00, signalling upside risk potential of 298.13%. On the other hand Rocket Pharmaceuticals, Inc. has an analysts' consensus of $7.95 which suggests that it could grow by 126.63%. Given that Artiva Biotherapeutics, Inc. has higher upside potential than Rocket Pharmaceuticals, Inc., analysts believe Artiva Biotherapeutics, Inc. is more attractive than Rocket Pharmaceuticals, Inc..

Artiva Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Rocket Pharmaceuticals, Inc. has a beta of 0.656, suggesting its less volatile than the S&P 500 by 34.373%.

Artiva Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rocket Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Artiva Biotherapeutics, Inc. pays -- of its earnings as a dividend. Rocket Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Artiva Biotherapeutics, Inc. quarterly revenues are --, which are smaller than Rocket Pharmaceuticals, Inc. quarterly revenues of --. Artiva Biotherapeutics, Inc.'s net income of -$21.5M is higher than Rocket Pharmaceuticals, Inc.'s net income of -$50.3M. Notably, Artiva Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Rocket Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artiva Biotherapeutics, Inc. is 46.79x versus -- for Rocket Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.